Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting article in March's "The Atlantic" ref short-selling...discusses current Justice Department investigation, citing reports that it's a probe of "possible coordination surrounding the publication of short reports, looking for signs of market manipulation or other trading abuses. The focus is on trading activity, not the content of the reports."
The same story quotes Elon Musk as saying SEC stands for "Shortseller Enrichment Commission."
Precisely correct.
I regret to say you've painted Linda's remarks in as glowingly bright colors as humanly possible--an optimistic interpretation on every phrase.
I believe the science, and the long-term outlook is good, maybe very good. But our CEO is a mediocre communicator. (She surely has been told this in the past. She needs coaching and better prep for public appearances.) Overly cautious in her statements? Perhaps. Still, her remarks were lacking luster and need the varnish you provide.
Her "forward-looking" statements advisory at the beginning would more accurately have been labeled "backward-looking."
Yes, the trial was a success. The company's communications are a mess, beginning with the CEO's inability to foster confidence.
Want just a symptom of poor planning? For at least three minutes, post-meeting room conversations were audible to people listening via the web because the system wasn't shut off.
So far Linda has only reported on the significant hurdles the company must clear to achieve success. The question is whether at some point she will tell us something that gives us confidence good days are ahead for patients and shareholders. To this point she sounds like a whining school girl trying to explain why her school project is incomplete. She needs some serious communication help. (Sigh)
Linda, we understand it's a massive undertaking. Would appreciate an expression of confidence that you are capable of seeing it through in 2023.
They're not doing too bad, considering they only have an annual meeting once every two or three years. :)
Frankly, for 401-K purposes, I wish the meeting began an hour or two later, after the market closed for the year.
This National Public Radio story today could (should) have been about what NWBO has to offer:
https://www.npr.org/sections/health-shots/2022/12/13/1140384354/crispr-improves-cancer-immunotherapy-car-t-cell
An example of why it's so important to get manufacturing/supply chain right...from today's Wall Street Journal...
=====================================================================================
A/S flubbed the launch of its buzzy new weight-loss drug Wegovy, missing out on hundreds of millions of dollars in sales and squandering a head start before a rival could begin selling a competing product.
Wegovy is among a new class of drugs that health regulators have approved to cut the weight of people who are obese, a goal long sought by doctors and patients. Their weight-dropping potential became a viral sensation on social media. Elon Musk tweeted about Wegovy in October. And a related drug for diabetes, Ozempic, is a hot topic in Hollywood among celebrities seeking to stay thin, according to doctors.
Yet Denmark-based Novo underestimated how big demand for the drug would be, and wasn’t ready to make enough to fill the prescriptions that flooded in after U.S. approval last year. Then a contract manufacturer halted production to address inspection issues.
“We should have forecasted better, which we did not,” Novo Chief Executive Lars Fruergaard Jørgensen said. “Had we forecasted that, we would have built a different supply chain.”
I seriously expected to wake up this morning to find a significant story ref the study results in either The Wall Street Journal or New York Times--or both. Even if there are partner or buyout talks underway, there is no reason the company shouldn't be spreading hopeful news to the medical, patient and regulatory communities.
I don't know much about science, but I do know something about journalism, public relations and marketing. This is a story that should have some wings, though the further we get removed from the JAMA article and the conference, the less appealing it becomes.
I can see no possible excuse for NWBO's dropping the ball here. Am I missing something?
Here's a fact: There's just over an hour's worth of trading left today. Shorts know NWBO's favorable news will spread in the hours leading up to this weekend's big conference and continue from there. In other words, a lot of them will decide they had better cover now--not later.
Don't be one of the chumps who lets the shorts cover with your shares.
Don't be one of the chumps who lets the shorts cover with your shares.
So when's the "annual" shareholders meeting?
How's this for a dream-on-but-it-could-happen scenario:
Journal (with remarkable findings) is published a few days before the conference and Dr. Liau begins conference with 10-minute observation about how the world of brain cancer treatments has now brightened for present and future victims, and how there may also now be a fresh standard of care for other types of cancer as well. Then every other presentation is viewed through a new and hopeful lens.
This is the email I received from David Innis on Aug. 21 in response to my inquiry about whether there would be an annual shareholders meeting this year:
"There will be an ASM this year and we are hoping it will be in September. Will Let everyone know when we have selected the date.
Best
Dave"
Thank you, ATLnsider, for sharing. There is hope for victims of this dreaded disease, and probably for NWBO investors, too!
Everything you say may be true, Doc...except the company has an obligation to inform shareholders of their company's standing on an annual basis regardless of its progress. Right?
Thanks. Hangin' in there. And blessings to you.
Getting pretty discouraged, Doc. Another week nearly gone with zero news and a downward pull in stock price. What do you make of the fact we've not had a shareholders meeting for so long?
The more prestigious SNO publication is published monthly; another appears to be published about six times per year.
Surprised she didn't say it was too far to walk.
Nice job. Your thoughtful summary lends hope to all longs and should inspire interest by those thinking about joining the list.
Every morning, Doc, I wake hoping approval news has broken in England while the U.S. slept...odds of that happening yet this calendar year?
Strange shade of red.
Again, from last Friday's "Wall Street Journal":
Biotech mergers have picked up and some expect more deals ahead, as big pharmaceutical companies sitting on cash, such as Pfizer Inc. with $33 billion, search for attractive biotech companies. Earlier this month, Pfizer agreed to buy Global Blood Therapeutics Inc., a biotech company that has one of the few approved treatments for sickle-cell disease, for $5.4 billion in cash. Profits from Pfizer’s Covid-19 vaccine have given the company the wherewithal to make more deals, investors say.
This month, Amgen Inc. agreed to acquire ChemoCentryx Inc., while Merck & Co. is in advanced talks to buy Seagen Inc., a biotech focused on cancer.
“We’ve been waiting and waiting, but M&A has finally woken up,” says healthcare investor Brad Loncar at Loncar Investments. “A company like Pfizer can spend tens of billions of dollars on M&A and not flinch.”
Strange shade of red.
Wrong, oh blindseerer...so wrong.
The things you suggest, of course, are all possible. Another (IMHO) distinct possibility: The company knows journal publication is imminent and recognizes how much more positive/smooth the ASM will be post-publication than if we were still being held in No-InfoLand.
Isn't there a likelihood that the journal article will have literally dozens of medical professionals who've endorsed it...and doesn't that really, really, really complicate/slow down the process?
There was only one signer/editor to this post. Me.
Speedy. But as we've all experienced (see post #507047), having two or more sets of eyes on a product is helpful.
My read is that Innes's reply to my inquiry implies that something standing in the way of scheduling the ASM could very well be resolved within the next couple of weeks. Most likely, IMHO, is journal publication.
I apologize...got ahead of myself. I received the message this morning: Monday, Aug. 22, 2022.
This morning (8/29/22)
Note from Dave Innes:
"There will be an ASM this year and we are hoping it will be in September. Will Let everyone know when we have selected the date.
Best
Dave"
From today's Wall Street Journal:
Biotech mergers have picked up and some expect more deals ahead, as big pharmaceutical companies sitting on cash, such as Pfizer Inc. with $33 billion, search for attractive biotech companies. Earlier this month, Pfizer agreed to buy Global Blood Therapeutics Inc., a biotech company that has one of the few approved treatments for sickle-cell disease, for $5.4 billion in cash. Profits from Pfizer’s Covid-19 vaccine have given the company the wherewithal to make more deals, investors say.
This month, Amgen Inc. agreed to acquire ChemoCentryx Inc., while Merck & Co. is in advanced talks to buy Seagen Inc., a biotech focused on cancer.
“We’ve been waiting and waiting, but M&A has finally woken up,” says healthcare investor Brad Loncar at Loncar Investments. “A company like Pfizer can spend tens of billions of dollars on M&A and not flinch.”
Yes, Teddy Roosevelt was one of their first patients.
Thank you. Patience is not my long suit, but insight like yours feeds it.
A key paragraph from the Houston Methodist site:
Most cancer drugs only achieve clinical benefits in a limited percentage of the patients with the type of cancer being targeted (e.g., 25 – 30% of the patients). In contrast, DCVax has achieved clinical benefits (i.e., longer delay in disease progression and longer extension of survival than with standard of care treatment) in over 80% of the patients who have received DCVax in clinical trials to date.
Yours is an excellent post, Doc. Yet it's hard to argue with many of Sir P's observations. Please reassure me and help me understand WHY this is taking so long. I've grown old waiting for something to happen.